Market PositionProprietary checks with medical oncologists reveal significant value in Tempus' technology platform and product suite, indicating a strong market position.
Revenue GrowthOverall core 'Genomics' revenue grew 27% year-over-year, led by higher average selling prices.
Strategic PartnershipsTempus announced an agreement worth $200mm with AstraZeneca and Pathos AI to develop the largest multimodal foundation model in oncology, representing a first of its kind partnership type for Tempus.